Arbutus Biopharma Corp
ABUS
Rank in Stocks
#10150
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company,... Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Share Price
$3.72
Last synced: 2026-11-09
Market Cap
$736.95M
Change (1 day)
1.78%
Change (1 year)
-21.02%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Arbutus Biopharma Corp (ABUS)
Category
Healthcare
Operating Margin for Arbutus Biopharma Corp (ABUS)
Operating Margin as of November 2026 TTM: 81.01%
According to Arbutus Biopharma Corp's latest financial reports, its current operating margin (TTM) is 81.01%. At the end of 2025 the company had an operating margin of -192.08%.
Operating Margin history for Arbutus Biopharma Corp from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 81.01% | -142.18% |
| 2025 | -192.08% | -84.47% |
| 2024 | -1,236.74% | 187.26% |
| 2023 | -430.53% | 156.65% |
| 2022 | -167.75% | -74.93% |
| 2021 | -669.11% | -19.97% |
| 2020 | -836.07% | -65.08% |
| 2019 | -2,393.96% | 57.29% |
| 2018 | -1,522.03% | 46.85% |
| 2017 | -1,036.45% | -96.84% |
| 2016 | -32,773.33% | 7,866.68% |
| 2015 | -411.38% | 86.99% |
| 2014 | -220.00% | 179.93% |
| 2013 | -78.59% | -14.22% |
| 2012 | -91.62% | 44.69% |
| 2011 | -63.32% | 8.04% |
| 2010 | -58.61% | -10.91% |
| 2009 | -65.79% | -42.08% |
| 2008 | -113.58% | -785.46% |
| 2007 | 16.57% | -234.06% |
| 2006 | -12.36% | -72.43% |
| 2005 | -44.83% | -80.26% |
| 2004 | -227.08% | -82.09% |
| 2003 | -1,268.10% | 132.06% |
| 2002 | -546.46% | 15.19% |
| 2001 | -474.40% | -8.87% |
| 2000 | -520.56% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.52% |
US
|
|
| -149.01% | -101.84% |
US
|
|
| 25.57% | -99.68% |
AU
|
|
| 31.23% | -99.61% |
BE
|
|
| 29.35% | -99.64% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Arbutus Biopharma Corp's operating margin
What is Arbutus Biopharma Corp's operating margin?
Arbutus Biopharma Corp's operating margin is 81.01%, as of Nov 2026.
What was Arbutus Biopharma Corp's operating margin in 2025?
In 2025, Arbutus Biopharma Corp's operating margin was -192.08%, compared with -1,236.74% in 2024.
How has Arbutus Biopharma Corp's operating margin changed since 2020?
From 2020 to 2025, Arbutus Biopharma Corp's operating margin was highest in 2022 (-167.75%) and lowest in 2024 (-1,236.74%).
How does Arbutus Biopharma Corp's operating margin compare with similar companies?
Arbutus Biopharma Corp's operating margin (81.01%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.